Two sessions at this year's American Society of Clinical Oncology meeting gave drug developers a glimpse of how to match more patients to clinical trials by broadening eligibility criteria and encouraging trial enrollment in community settings.
Both measures could increase patient enrollment, especially in rare indications or those where enrollment at academic centers is competitive, and they could increase access to patients who better reflect the diversity in the real world.
According to ASCO presenters and panelists, more than 80% of patients live near a community hospital or practice, but only about 3-5% of them enroll in a clinical trial compared with 7-10% of patients living near an academic hospital.
"Community is a very, very viable option. Pharmas should not necessarily go back to the same well over and over again hoping that the patients show up," Carla Balch, CEO of Inteliquet Biopharma, told BioCentury. Inteliquet, which uses real-world data to find and match patients with clinical trials, presented at a separate ASCO session.
“Sponsors need to choose sites based